Re-Evaluation of the Anticoagulant Properties of High-Density Lipoprotein-Brief Report

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 3, 2015, Pages 570-572

  Fernandez, Jose A ^a   Deguchi, Hiroshi ^a   Banka, Carole L ^b   Witztum, Joseph L ^b   Griffin, John H ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

High density lipoproteins; Protein C; Protein S; Thromboplastin; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; HIGH DENSITY LIPOPROTEIN; PROTEIN S; ANTICOAGULANT AGENT; APOA1 PROTEIN, HUMAN; APOLIPOPROTEIN A1; FIBRINOLYTIC AGENT; PROTEIN C;

ANTICOAGULATION; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; PROTEIN FUNCTION; STORAGE TEMPERATURE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; CHROMATOGRAPHY; COLD; DRUG EFFECTS; HUMAN; METABOLISM; PROCEDURES; PROTEIN DENATURATION; PROTEIN STABILITY; TIME FACTOR;

ANTICOAGULANTS; APOLIPOPROTEIN A-I; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CENTRIFUGATION, DENSITY GRADIENT; CHROMATOGRAPHY; COLD TEMPERATURE; FIBRINOLYTIC AGENTS; HUMANS; LIPOPROTEINS, HDL; PROTEIN C; PROTEIN DENATURATION; PROTEIN S; PROTEIN STABILITY; TIME FACTORS;

EID: 84920475329     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304938     Document Type: Article

References (11)

1. Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014;384:618-625. doi:10.1016/S0140-6736(14)61217-4.
2. Durrington P. Dyslipidaemia. Lancet. 2003;362:717-731. doi:10.1016/ S0140-6736(03)14234-1.
3. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117:93-102. doi:10.1161/CIRCULATIONAHA.107.709204.
4. Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. Highdensity lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation. 2005;112:893-899. doi:10.1161/ CIRCULATIONAHA.104.521344.
5. Eichinger S, Pecheniuk NM, Hron G, Deguchi H, Schemper M, Kyrle PA, Griffin JH. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation. 2007;115:1609-1614. doi:10.1161/ CIRCULATIONAHA.106.649954.
6. Vayá A, Falcó C, Simó M, Ferrando F, Mira Y, Todolí J, España F, Corella D. Influence of lipids and obesity on haemorheological parameters in patients with deep vein thrombosis. Thromb Haemost. 2007;98:621-626.
7. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98:1352-1364. doi:10.1161/01. RES.0000225982.01988.93.
8. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernández JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 1999;103:219-227. doi:10.1172/ JCI5006.
9. Oslakovic C, Norstrøm E, Dahlbäck B. Reevaluation of the role of HDL in the anticoagulant activated protein C system in humans. J Clin Invest. 2010;120:1396-1399. doi: 10.11722/JCI42260.
10. Oslakovic C, Krisinger MJ, Andersson A, Jauhiainen M, Ehnholm C, Dahlbäck B. Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins. J Biol Chem. 2009;284:5896-5904. doi:10.1074/jbc.M807286200.
11. Rumsey SC, Galeano NF, Arad Y, Deckelbaum RJ. Cryopreservation with sucrose maintains normal physical and biological properties of human plasma low density lipoproteins. J Lipid Res. 1992;33:1551-1561.